LENSAR is a commercial-stage medical device company focused on designing, developing and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Co.'s existing LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining better visual outcomes, efficiency and reproducibility. Co. is also designing, developing, and seeking regulatory clearance of a system, its ALLY Adaptive Cataract Treatment System, which combines an improved femtosecond laser with a phacoemulsification system in a single, integrated cataract treatment system. We show 15 historical shares outstanding datapoints in our coverage of LNSR's shares outstanding history.
Understanding the changing numbers of LNSR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like LNSR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching LNSR by allowing them to research LNSR shares outstanding history
as well as any other stock in our coverage universe. |
Free LNSR Email Alerts:
Video: Shares Outstanding Importance
